The US Food and Drug Administration (FDA) has said that the currently approved dose of GlaxoSmithKline and Vir Biotechnologys COVID-19 antibody treatment is unlikely to work against the Omicron BA.2 variant.

The FDA pulled the authorization for sotrovimab in most of the U.S. northeast where the subvariant was dominating. As per government data, the highly transmissible BA.2 variant causes about one-in-three COVID-19 cases in the United States at present.

The companies stated that they are working on a package of data supporting a higher dose of sotrovimab than the currently authorized 500 mg dose, targeted at the BA.2 subvariant. The data will be shared with regulatory authorities globally for review… (Reuters, March 26, 2022)